Off-Label Audience Of One: Exhibit Booths Should Aim For Personal Conversations
This article was originally published in The Pink Sheet Daily
Executive Summary
When responding to an unsolicited request for information on an off-label use of a drug at a medical conference, it’s important that firms ensure only the person who asked the question receives the answer, compliance experts suggest.
You may also be interested in...
Off-Label Use Discussions Should Stay Off-line, FDA Draft Guidance Says
FDA advises companies to respond to unsolicited requests for off-label information in one-on-one dialogue; the agency also requests public comments on its policies regarding off-label communications in response to an industry citizen petition.
ASCO advertising letters continue
FDA ad division letters cites Aventis for Taxotere (docetaxel) promotional brochure describing an unapproved indication and SkyePharma/Chiron for solicitation of off-label information requests for DepoCyt at the American Society of Clinical Oncology meeting in May. FDA has issued at least 11 letters regarding promotions at the meeting (1"The Pink Sheet" Aug. 6, p. 6)
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.